A detailed history of Vanguard Group Inc transactions in Arvinas, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 6,299,556 shares of ARVN stock, worth $209 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
6,299,556
Previous 4,851,390 29.85%
Holding current value
$209 Million
Previous $200 Million 30.23%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$36.38 - $52.31 $52.7 Million - $75.8 Million
1,448,166 Added 29.85%
6,299,556 $260 Million
Q4 2023

Feb 14, 2024

BUY
$14.19 - $42.33 $3.45 Million - $10.3 Million
243,167 Added 5.28%
4,851,390 $200 Million
Q3 2023

Nov 14, 2023

BUY
$19.64 - $28.21 $1.78 Million - $2.55 Million
90,426 Added 2.0%
4,608,223 $90.5 Million
Q2 2023

Aug 14, 2023

BUY
$21.73 - $31.43 $518,760 - $750,328
23,873 Added 0.53%
4,517,797 $112 Million
Q1 2023

May 15, 2023

BUY
$26.15 - $37.26 $958,842 - $1.37 Million
36,667 Added 0.82%
4,493,924 $123 Million
Q4 2022

Feb 10, 2023

BUY
$32.47 - $57.24 $9 Million - $15.9 Million
277,192 Added 6.63%
4,457,257 $152 Million
Q3 2022

Nov 14, 2022

BUY
$41.87 - $57.99 $4.89 Million - $6.78 Million
116,877 Added 2.88%
4,180,065 $186 Million
Q2 2022

Aug 12, 2022

BUY
$36.01 - $74.24 $1.43 Million - $2.94 Million
39,607 Added 0.98%
4,063,188 $171 Million
Q1 2022

May 13, 2022

BUY
$60.27 - $81.57 $1.89 Million - $2.56 Million
31,372 Added 0.79%
4,023,581 $271 Million
Q4 2021

Feb 14, 2022

BUY
$65.85 - $96.21 $12.6 Million - $18.4 Million
191,277 Added 5.03%
3,992,209 $328 Million
Q3 2021

Nov 12, 2021

BUY
$73.2 - $107.87 $9.47 Million - $13.9 Million
129,320 Added 3.52%
3,800,932 $312 Million
Q2 2021

Aug 13, 2021

BUY
$60.45 - $84.26 $222 Million - $309 Million
3,671,612 New
3,671,612 $283 Million

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.76B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.